Internal Med Medical News about endocrine carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
Endocrine-Related Cancer, 06/04/09

Durante C et al. - In a study to evaluate the long-term outcome and prognostic factors for survival in pts with distant metastases from gastroenteropancreatic well-differentiated endocrine carcinoma (GEP WDEC), this study enables the stratification of metastatic GEP WDEC pts into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and to design and interpret clinical trials.

Methods

Long-term outcome and prognostic factors for survival were evaluated in 118 pts with distant metastases from GEP WDEC.
Inclusion criteria included pathological review by a single pathologist according to WHO criteria, absence of previous therapy apart from surgery, complete morphological evaluation within 3 mos including somatostatin receptor scintigraphy, and follow-up at Gustave-Roussy Institute until death or study's end.
Clinical, biological marker, and pathological parameters were analyzed in univariate and multivariate statistical models.
Survival after the first complete imaging work-up of the metastatic disease was determined using Kaplan–Meier method.

Results

Survival for 5 yrs after diagnosis of metastatic disease was 54%.
In multivariate analysis, age, number of liver metastases, tumor slope, and initial surgery were predictive of survival.
5-yr survival was 100%, 91%, 62%, and 9% when pts had 0, 1, 2, 3, or more poor prognostic features, respectively.

<< Previous
A New Monitoring Method for the Estimation of Body Fluid Status...

Next >>
Results of the PROspective MInnesota Study of ECHO/TDI in Cardiac...

Neurofibroma adjacent to the thyroid gland and a thyroid papillary carcinoma in a patient with neurofibromatosis type 1: Report of a case
Surgery Today, 10/06/09 Relevance Score: 66%

Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification
Histopathology, 11/11/09 Relevance Score: 65%

S100A8 and S100A9 Expression Is a Crucial Factor for Dedifferentiation in Thyroid Carcinoma
Anticancer Research, 11/11/09 Relevance Score: 65%

Continuous 5-fluorouracil infusion plus long acting Octreotide in advanced well differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network.
BMC Cancer, 11/09/09 Relevance Score: 65%

RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact
Journal of Clinical Endocrinology and Metabolism, 10/21/09 Relevance Score: 65%